Our constant curiosity and specialist approach drive our innovation and bring new ideas to life. We have a proud history of advancing care in multiple sclerosis and pioneering new discoveries in immunology & immune-based diseases for more than 20 years.
We are growing a strategic pipeline with a range of new potential therapies that may be able to alter treatment paradigms for chronic conditions, such as multiple sclerosis (MS), systemic lupus erythematosus (SLE) and forms of arthritis, including rheumatoid arthritis (RA) and osteoarthritis (OA).
We are discovering new ways to optimize outcomes for a range of chronic progressive diseases by pursuing novel pathways that can modulate the immune system in a more targeted way than traditional immunosuppressants.
For immune disorders, we develop approaches that target the innate and adaptive components of the immune system. This includes inhibiting the inappropriate immune activation that contributes to the disorder, as well as enhancing immune tolerance, which trains the body not to react to autoreactive triggers.
For the treatment of certain types of arthritis, our investigational therapies are being developed to potentially feature approaches that may facilitate cartilage repair homeostasis (a balance of re-growing cartilage and stopping cartilage from breaking down).
We aim to deliver first & best in class therapies to patients, we continue to combine our world-class internal scientific expertise with strategic external partnerships and collaborative research alliances that maximize the opportunities for our pipeline and optimize our R&D.
Browse the programs in our pipeline to see our current focus. Learn more